Equity Research Database

Institutional Investment Pitches

Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.

Home Letters Funds Account

Andrew Hill Investment Advisors, Inc.'s investment thesis on Vertex Pharmaceuticals Incorporated ($VRTX) — Q2 2026 | Buyside Digest

All Pitches

View Letter Analysis

$VRTXNASDAQVertex Pharmaceuticals Incorporated

NEUTRAL

Andrew Hill Investment Advisors, Inc.—VRTX

Fund Letter

Q2 2026

Published July 6, 2026

View Fund Profile

$522.81USD

-4.3% vs last month

$485.39Pitched

+7.7% since pitch

Market Cap$122.4B

P/E (TTM)N/A

52-Wk RangeN/A

Div. YieldN/A

Technical Chart

From the Fund Letter

Andrew Hill Investment Advisors navigated a narrow Q2 2026 rally driven by AI and technology earnings, with S&P 500 up 13% but performance concentrated in ten stocks. The firm lagged...

— Andrew D.W. Hill

BSD Research Exclusive

Unlock Full Institutional Investment Theses

Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.

6,000+ Institutional Pitches

Proprietary AI Analysis

100 Letter Unlocks/Cycle

SUBSCRIBE TO BSD RESEARCH ($55/MO)Compare All Plans

Already a Research or Pro subscriber? Sign In

◆ Keep Reading

What other investors think about $VRTX, and what else Andrew Hill Investment Advisors, Inc. is buying.

Other pitches on $VRTX

Other investors who've written on Vertex Pharmaceuticals Incorporated

No other institutional pitches found for this ticker yet.

View all $VRTX pitches →